我国乙肝创新药物临床研究取得突破性进展

Core Insights - The 76th American Association for the Study of Liver Diseases (AASLD) annual meeting opened in Washington, D.C., showcasing significant advancements in liver disease research and treatment [1] - Chinese research teams presented multiple reports at the AASLD 2025 conference, highlighting breakthroughs in hepatitis B research, clinical diagnosis, new drug development, liver cancer mechanisms, cirrhosis, and fatty liver disease [1] - Hepu Pharmaceutical's innovative hepatitis B drug, Hepulapta, demonstrated breakthrough results in a Phase II randomized double-blind clinical trial, addressing the global challenge of interferon resistance in hepatitis B treatment [1][2] Drug Development - Hepulapta, developed by Hepu Pharmaceutical, utilizes a unique mechanism to block HBV virus entry into liver cells, significantly enhancing the clinical efficacy of interferon treatment [2] - The drug showed potential in reversing interferon resistance in "big three positive" hepatitis B patients during Phase II clinical trials, achieving international standards for viral clearance [2] Public Health Impact - The advancements in hepatitis B treatment from China are expected to contribute to the World Health Organization's (WHO) goal of eliminating viral hepatitis as a major public health threat by 2030 [2] - These developments align with the objectives of the "Healthy China 2030" initiative, providing strong support for public health goals in China [2]